About Spansa Pharmaceuticals Private Limited
Data last updated:
Spansa Pharmaceuticals Private Limited is a private limited company based in Patna, Bihar, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 September 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Patna, under CIN U24232BR2012PTC019175. Its GSTIN is 10AASCS0388J1Z3 (Bihar). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Ram Gopal Jayaswal and Anuj Kedia.
Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Ground Floor And First Floor Nc – 4B Nandan Bhawan Gayatri Mandir Road Kankarbagh, Patna, Bihar, India – 800020.
As per the financials filed for FY 2025, the company reported a revenue of ₹8.15 Cr, a growth of 20% compared to the previous year. For the same year it recorded a net profit of ₹19.57 Lakh (net margin 2.4%) and EBITDA of ₹59.21 Lakh (EBITDA margin 7.3%). Revenue has grown at a compounded annual rate (CAGR) of 17% over three years and 22% over five years.
As per MCA filings, the company has open charges of ₹2.33 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website spansapharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressGround Floor And First Floor Nc – 4B Nandan Bhawan Gayatri Mandir Road Kankarbagh, Patna, Bihar, India – 800020
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Spansa Pharmaceuticals Private Limited
The main business activity of Spansa Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Spansa Pharmaceuticals Private Limited FY 2025 filings available
Spansa Pharmaceuticals Private Limited reported revenue of ₹8.15 Cr (up 20% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Spansa Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 22% over five years, including 20% growth in the latest year. EBITDA rose 7% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Spansa Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹59.21 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹19.57 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Spansa Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 7.3% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 2.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Spansa Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Profess Health Products Private Limited | ₹8.2 Cr (FY 2024) | •••• | •••• | 11.0% | •••• | Lucknow, Uttar Pradesh, India |
| Dupen Laboratories Private Limited | ₹8.2 Cr (FY 2025) | •••• | •••• | -35.0% | •••• | Mumbai, Maharashtra, India |
| Ags Pharmaceuticals Private Limited | ₹8.19 Cr (FY 2024) | •••• | •••• | -17.0% | •••• | Thirupathur, Tamil Nadu, India |
| KFS Biotech Private Limited | ₹8.15 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Baddi, Himachal Pradesh, India |
| Gujarat Mitul Petro -Pharma Private Limited | ₹8.15 Cr (FY 2024) | •••• | •••• | -19.0% | •••• | Vadodara, Gujarat, India |
| Spansa Pharmaceuticals Private Limited this company | ₹8.15 Cr (FY 2025) | •••• | •••• | 20.0% | •••• | Patna, Bihar, India |
| Sini Pharma Private Limited | ₹8.13 Cr (FY 2025) | •••• | •••• | 259.0% | •••• | Ahmedabad, Gujarat, India |
| KST Pharmaceuticals Private Limited | ₹8.12 Cr (FY 2024) | •••• | •••• | 552.0% | •••• | Hyderabad, Telangana, India |
| Convallaer Pharmaceuticals Private Limited | ₹8.1 Cr (FY 2024) | •••• | •••• | 36.0% | •••• | Kanpur, Uttar Pradesh, India |
| Pasvid Global Private Limited | ₹8.1 Cr (FY 2024) | •••• | •••• | 50.0% | •••• | Morewasti, Maharashtra, India |
| Sanghvi Pharmachem Pvt Ltd | ₹8.09 Cr (FY 2025) | •••• | •••• | 4.0% | •••• | Ahmedabad, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Spansa Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals Private Limited is audited by B K PANDEY & CO for the financial year 2021.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| B K PANDEY & CO | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals has 3 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ram Gopal Jayaswal | Director | 27 Jul 2021 | 5 Years 2 Months | Current |
| Anuj Kedia | Director | 29 Oct 2018 | 7 Years 11 Months | Current |
| Ayush Kumar Kediya Also directs: Spansa Wellness LLP | Director | 03 Sep 2012 | 14 Years 1 Months | Current |
Ownership and Shareholding of Spansa Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Spansa Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Nov 2024 | Hdfc Bank Limited | ₹36 Lakh | Open |
| 21 Aug 2023 | Hdfc Bank Limited | ₹17 Lakh | Open |
| 23 Jul 2021 | Hdfc Bank Limited | ₹30.42 Lakh | Open |
| 31 Jan 2019 | Hdfc Bank Limited | ₹1.5 Cr | Open |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals Private Limited has a workforce of 0 employees as of Apr 03, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals Private Limited has 9 board changes on record since 2012: 3 appointments and 6 cessations. The latest: Ram Gopal Jayaswal ceased to be Additional Director on 31 Oct 2021.
5 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Spansa Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Spansa Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Spansa Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AASCS0388J1Z3 | Bihar | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Spansa Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spansa Pharmaceuticals Private Limited
Spansa Pharmaceuticals is an active private limited company based in Patna, Bihar, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 September 2012 (14+ years old) and is registered under CIN U24232BR2012PTC019175.
Spansa Pharmaceuticals reported revenue of ₹8.15 Cr for FY 2025 (up 20% YoY).
Spansa Pharmaceuticals has 3 current directors:
- Ram Gopal Jayaswal - Director
- Anuj Kedia - Director
- Ayush Kumar Kediya - Director
Spansa Pharmaceuticals reported a net profit of ₹19.57 Lakh (net margin 2.4%) and EBITDA of ₹59.21 Lakh (EBITDA margin 7.3%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Spansa Pharmaceuticals is 17% over three years and 22% over five years. In the latest year (FY 2025) revenue rose 20%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Spansa Pharmaceuticals is 10AASCS0388J1Z3, registered in Bihar. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Spansa Pharmaceuticals is U24232BR2012PTC019175. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Spansa Pharmaceuticals was incorporated on 03 September 2012, making it 14+ years old. It is registered with the Registrar of Companies, Patna.
The peers of Spansa Pharmaceuticals by revenue are Profess Health Products Private Limited, Dupen Laboratories Private Limited, Ags Pharmaceuticals Private Limited, KFS Biotech Private Limited, Gujarat Mitul Petro -Pharma Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Ram Gopal Jayaswal ceased to be Additional Director on 31 Oct 2021. Ram Gopal Jayaswal was appointed as Director on 27 Jul 2021. Anuj Kedia ceased to be Additional Director on 28 Sep 2019. Spansa Pharmaceuticals has 9 board changes on record in total.
Spansa Pharmaceuticals can be reached through the website spansapharma.com. Its registered office is in Patna, Bihar, India.